Emer Leahy

Ph.D.

Dr. Emer Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with three partnered Phase II clinical programs and Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine, Dr. Leahy has more than 25 years of experience in drug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Prior to her appointment as CEO of PsychoGenics, she was Vice President of Business Development, a position she also held at American Biogenetic Sciences and at AMBI Inc. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), and currently serves on the Business Review Board for the Alzheimer’s Drug Discovery Foundation and the Scientific Advisory Board of the International Rett Syndrome Foundation.

Back to Our Team
Back to Top